Renoprotection with and without blood pressure reduction

Kidney International, Supplement

Volumn 67, Issue 94, 2005, Pages

  Laverman, Gozewijn Dirk ^a   Andersen, Steen ^b   Rossing, Peter ^b   Navis, Gerjan ^b   De Zeeuw, Dick ^b   Parving, Hans Henrik ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Albuminuria; Blood pressure response; Diabetes mellitus; Losartan; Proteinuria; Renoprotection

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; ANTIHYPERTENSIVE AGENT;

ADULT; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; ALBUMINURIA; CLINICAL PRACTICE; DRUG DOSE REDUCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; MIDDLE AGED; RENOVASCULAR HYPERTENSION;

ADULT; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION, RENAL; LOSARTAN; MALE; MIDDLE AGED;

EID: 15944429284     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. MARCANTONI C, JAFAR TH, OLDRIZZI L, et al: The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney Int 57(Suppl 75):44-48, 2000
2. JAFAR TH, STARK PC, SCHMID CH, et al: Proteinuria as a modifiable risk factor for the progression of nondiabetic renal disease. Kidney Int 60:1131-1140, 2001
3. PARVING HH, ANDERSEN AR, SMIDT UM, SVENDSEN PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175-1179, 1983
4. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
5. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
6. DE JONG PE, NAVIS G, DE ZEEUW D: Renoprotective therapy: Titration against urinary protein excretion. Lancet 354:352-353, 1999
7. WEIDMANN P, BOEHLEN LM, DE COURTEN M: Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 8:582-584, 1993
8. LAVERMAN GD, HENNING RH, DE JONG PE, et al: Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 38:1381-1384, 2001
9. ANDERSEN S, ROSSING P, JUHL TR, et al: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 17:1413-1418, 2002
10. PALLA R, PANICHI V, FINATO V, et al: Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 14:35-43, 1994
11. WEINBERG MS, WEINBERG AJ, CORD R, ZAPPE DH: The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein secretion. J Renin Angiotensin Aldosterone Syst 2:S196-S198, 2001
12. CONLIN PR, SPENCE JD, WILLIAM SB, et al: Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens 13:418-426, 2000
13. HEEG JE, DE JONG PE, VAN DER HEM GK, DE ZEEUW D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-279, 1989
14. RUDBERG S, APERIA A, FREYSCHUSS U, PERSSON B: Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 33:470-476, 1990
15. THE ACE INHIBITORS IN DIABETIC NEPHROPATHY TRIALIST GROUP: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379, 2001
16. RITZ E, RYCHLIK I, SCHOMIG M, WAGNER J: Blood pressure in diabetic nephropathy-current controversies. J Intern Med 249:215-223, 2001
17. PETERS H, RITZ E: Dosing angiotensin II blockers-Beyond blood pressure. Nephrol Dial Transplant 14:2568-2570, 1999
18. PRAGA M: Slowing the progression of renal failure. Kidney Int 61(Suppl 80):18-22, 2002
19. ANDERSEN S, TARNOW L, ROSSING P, et al: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601-606, 2000
20. BOS H, ANDERSEN S, ROSSING P, et al: Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 57:S32-S37, 2000
21. LAVERMAN GD, NAVIS G, HENNING RH, et al:Dualrenin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62:1020-1025, 2002
22. LAVERMAN GD, DE ZEEUW D, NAVIS GJ: Between-patient differences in the renal response to renin-angiotensin system intervention: Clue to optimising renoprotective therapy? J Renin Angiotensin Aldosterone Syst 3:205-213, 2002
23. PETERSON JC, ADLER S, BURKART JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
24. RUGGENENTI P, PERNA A, MOSCONI L, et al: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53:1209-1216, 1998
25. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252-1256, 1998
26. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001